Not likely here. Biogen Idec is a 'real' pharma, with drugs and pipeline, etc. - cash out.
DNDN is a start-up, albeit late-stage development.
DNDN has lined up financing to be going-it-alone, or at least, to be in a position to go it alone. Meaning, they're not scrambling for cash or a partner... if one came along with a great deal to offer, then they might take it.
Interesting (yet wacky) was the Kirin Brewery deal from Japan. What's up with that? Well, there's a foreign partnership for 'ya! Would have made a better story if it was Takeda.